Evaluation of the effect of oral prolive on liver function in patients with major and intermediate thalassemia

Evaluation of the effect of oral proliveon liver function in patients with major and intermediate thalassemia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191010045050N1

Enrollment

Registered

2020-01-05

Start date

2019-12-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major and intermedia thallassemia. Other disorders of blood and blood-forming organs in diseases classified elsewhere

Interventions

Intervention 1: Intervention group: At baseline, liver enzymes levels of ALT, AST, total cholesterol, total protein, ALKp, total bilirubin and GGT will be measured by ELISA in the control group.patien

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: All patients with beta thalassemia major and intermedia over 5 years

Exclusion criteria

Exclusion criteria: Patients not willing to participate in the study Malignancy Liver dysfunction

Design outcomes

Primary

Measure	Time frame
Liver enzyme. Timepoint: Before the intervention and after, every one month to six months. Method of measurement: Laboratory.;Total Billirubin and Total protein. Timepoint: Before the intervention and after, every one month to six months. Method of measurement: Laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzam Ebrahimi

Arak University of Medical Sciences

azame7733@gmail.com+98 86 3312 7359

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026